Lambrinex (Atorvastatin)

Atorvastatin inhibits the enzyme HMG‑CoA reductase, which is essential for cholesterol synthesis in the liver. This inhibition reduces internal cholesterol production, increases LDL‑receptor expression, and enhances removal of LDL cholesterol from the bloodstream.

The appropriate dose of Lambrinex is determined by a qualified prescriber based on the patient’s cholesterol levels, cardiovascular risk profile, and tolerance. Dosage adjustments are made according to clinical response and laboratory monitoring.

Lambrinex is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of potential fetal harm. It is also not recommended while breastfeeding, as the drug may pass into breast milk and affect the infant.

To place an order, submit an enquiry on the Lambrinex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Lambrinex (atorvastatin) is a high‑potency statin with a long half‑life, allowing flexible dosing and strong LDL‑cholesterol reduction. Compared with lower‑intensity statins such as pravastatin, atorvastatin often achieves greater lipid lowering at comparable doses, but individual response and tolerability guide therapy choice.

Lambrinex should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Lambrinex is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or split the tablet unless specifically instructed.

The most serious risks include rhabdomyolysis, a severe muscle breakdown that can lead to kidney failure, and significant liver injury. Patients should promptly report unexplained muscle pain, weakness, or dark urine, and undergo regular liver function monitoring.

Lambrinex should not be used by individuals with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to atorvastatin, or by pregnant women. It is also contraindicated in patients taking certain strong CYP3A4 inhibitors.